Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement

Provision Language

9. Confidential Information and Publication

9.2 Scientific Publication. Subject to the rights granted to each Party pursuant to this Agreement and the requirements of this Article 9, each Party will have the right to publish the results of the Research Program provided that:

(a) a copy of any proposed disclosure is given to the other Parties for review (i) in the case of a manuscript, and all revisions thereof, at least [**] days prior to the date of submission for publication or of public disclosure, (ii) in the case of a draft abstract, at least [**] days prior to the date of submission for publication or public disclosure, or (iii) in the case of a final abstract, at least [**] days prior to the date of submission for publication or public disclosure. An abstract submitted in draft form will not have to be resubmitted to the other Parties provided that the abstract is not modified in the final draft to include information that was not included in prior drafts and is not otherwise materially or substantively modified;

(b) any reference to a Party’s Confidential Information (other than any Program Development) is deleted if required by such Party;

(c) the publication or disclosure includes an appropriate acknowledgment of Alnylam’s sponsorship of the Research Program and each Party’s participation in the Research Program; and

(d) if Alnylam determines that a Program Development is contained in the disclosure, such Party agrees to defer publication or disclosure for up to [**] days from the time Alnylam notifies such Party that it wants to file or have filed a patent application on the Program Development.